EHA 2022 | The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALL
Sara Ghorashian
• 12 Jun 2022
In this video, Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK talks on the use of CAR-T therapy in combination with antibodies for the treatment of acute lymphoblastic leukemia (ALL). The high efficacy of blinatumomab for treatment of relapsed/refractory ALL (R/R ALL) is discussed. However, Dr Ghorashian highlights concerns regarding the use of blinatumomab prior to CAR T-cell therapy, and emphasizes that further investigation is needed to improve treatment approaches and sequencing of therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis, UCLB.
